vTv Therapeutics
vTv Therapeutics Logo
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small molecule therapeutics for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin (TTP399), is in Phase III trials for type 1 and type 2 diabetes. The company is also advancing other drug candidates targeting conditions such as cystic fibrosis-related diabetes, psoriasis, COPD, atopic dermatitis, and chronic diseases associated with oxidative stress. vTv Therapeutics collaborates with various partners to develop and commercialize its pipeline of drug candidates.
Address
3980 Premier Drive, Suite 310
High Point, 27265
United States
Year founded
2015
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
